Search
Menu
Home
HTB
2024
March
March 2024
Contents
Editorial
UK guide to PrEP now online: major update (2024)
Conference reports
CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda
CROI 2024: Pipeline ART – new drugs and formulations
CROI 2024: Studies using tecovirimat to treat mpox
CROI 2024: Promising results from first study of long-acting treatment in Africa
CROI 2024: HIV studies with semaglutide: significant benefits but limited access for treatment and research
CROI 2024: studies to watch for at this upcoming conference
Antiretrovirals
Roche to discontinue enfuvirtide (T-20, Fuzeon)
Guidelines
US guidelines recommend earlier use of statins in people living with HIV
HTB RSS
Early access
RIO study: Dual-bNABs keep viral load undetectable off-ART – plus a potential first case of vaccine-like HIV remission
12 March 2025
CROI 2025: Introduction to this year’s conference
9 March 2025
CROI 2025: Stand Up For Science rally against Trump funding freeze
9 March 2025
CROI 2025: Jay Bhattacharya is proposed to head the US NIH which would further wreck global science
7 March 2025
All early access reports
Current issues
March 2025
February 2025
January 2025
Back issues
Special report
Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer
1 March 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate